{"schema_version":"secwatch.filing_event.v1","accession":"0001544227-22-000004","form_type":"8-K","ticker":"TPST","cik":"0001544227","company_name":"Tempest Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.098218+00:00","generated_at":"2026-06-22T03:34:10.204348+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Tempest Q3 2022 net loss $8.9M; cash at $42.8M; pipeline milestones on track","bullets":["Cash and equivalents $42.8M as of Sep 30, 2022, down from $51.8M at Dec 31, 2021.","Net loss Q3 2022 of $8.9M ($0.66/sh) vs $8.1M ($1.21/sh) in Q3 2021.","R&D expense increased to $6.0M from $4.6M on expanded R&D efforts.","TPST-1120 Phase 1b/2 HCC study with Roche; early data from first 40 patients expected H1 2023.","TPST-1495 Phase 1 dose optimization data expected by year-end or early 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001544227-22-000004","json":"https://secwatch.observer/filing/0001544227-22-000004.json","markdown":"https://secwatch.observer/filing/0001544227-22-000004.md","text":"https://secwatch.observer/filing/0001544227-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/0001544227-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/tpst-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:34:10.204348+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44b30594d1be2c4535a8bd490045ba6aa8fe7500","claim":"Tempest Therapeutics, Inc. reported the third fiscal quarter ended September 30, 2022 results: net income $8.9 million, EPS $0.66.","evidence_excerpt":"Net loss and net loss per share for the third quarter of 2022 were $8.9 million and $0.66, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1544227/000154422722000004/0001544227-22-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third fiscal quarter ended September 30, 2022"},{"label":"Net income","value":"$8.9 million"},{"label":"EPS","value":"$0.66"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}